Introduction
============

With the highest mortality rate among all cancers in China and many other countries, lung cancer annually causes approximately 1.38 million deaths worldwide [@B1], [@B2]. Lung cancer is histologically sub-classified into four categories: lung adenocarcinoma (LUAD), squamous cell carcinoma (LUSC), large cell carcinoma, and small cell carcinoma of the lung. LUAD, an epithelial cancer of glandular origin, is the most common pathological subtype of non-small cell lung cancer (NSCLC), even for never-smokers [@B3], [@B4]. Since LUAD is a heterogeneous tumor with diverse molecular, clinical, and pathological characteristics, the identification of oncogenic drivers has increased understanding of LUAD biology [@B5], [@B6].

Recognition of molecular alterations in LUAD has facilitated tailored therapy targeting these alterations and has ushered in the era of "personalized" oncologic medicine. For example, LUAD patients with activating mutations of the epidermal growth factor receptor gene (*EGFR*) have a better response to *EGFR* tyrosine kinase inhibitors (TKIs) than those without *EGFR* mutations [@B7], and rearrangement of the anaplastic lymphoma kinase gene (*ALK*) is the best predictor of LUAD response to the *ALK* TKI crizotinib [@B8]-[@B10]. These facts indicate that therapeutic effectiveness is linked to the presence of specific oncogenomic alterations. However, patients with *EGFR* mutations or *ALK* fusion account for only one-third of patients diagnosed with LUAD [@B11], which indicates the necessity of understanding of the genetic basis for LUAD without *EGFR* mutations or *ALK* fusion.

The molecular mechanisms underlying LUAD development are unclear, and the heterogeneous nature of lung cancer makes it difficult to achieve an understanding. It is not known if LUAD patients with *EGFR/ALT* alterations harbor distinct genetic characteristics compared to those without such alterations. Moreover, little is understood about the correlation of copy numbers and gene expression of top-ranked genes in lung cancer, especially for LUAD without *EGFR* mutations or *ALK* fusion. In addition, since the development and progression of LUAD are consequences of gene-gene interactions and regulatory coordination [@B12]-[@B14], the identification of therapeutic targets in regulatory pathways can provide insight into the etiology and pathogenesis of LUAD. Whether and how these lung cancer-associated genes are coordinated to affect cellular functions remain largely unexplored.

In the present study, we retrospectively analyzed genomic sequencing data for LUAD and LUSC patients. Oncogenomic alterations of 23 top candidate genes were assessed to explore the similarities and differences between these two lung cancer types. The copy numbers of these candidate genes were further evaluated in ten micro-dissected LUADs without *EGFR* mutations or *ALK* fusion. For a few genes, further exploration of the associations between copy number and gene expression was conducted. This study revealed a concordant change of *PTEN* at both genomic DNA and mRNA levels in LUAD without *EGFR* mutation or *ALK* fusion. The results provide an approach to validating molecules involved in lung carcinogenesis and a basis for identifying pathways as targets for the treatment of LUAD.

Materials and Methods
=====================

Human tissue specimens
----------------------

Specimens, including tumor tissue and tumor-distant normal lung tissue from the same patient, were collected from ten patients with LUAD who underwent primary surgery between January 2009 and June 2012 at the First Hospital of Jiamusi University. This study involving human lung tumor tissues has been approved by the Institutional Review Board of the First Hospital of Jiamusi University. Informed consent was obtained from all human subjects in accordance with the requirements of the Institutional Review Board. At the time of LUAD diagnosis, all patients were naïve for chemo-, radio-, and targeted therapy. They did not receive any other treatment that could induce mutations. Patients were excluded if (1) they previously received radio-, chemo-, or targeted therapy; (2) their histological samples were insufficient for genetic testing; or (3) they were diagnosed with metastatic LUAD. Clinicopathological characteristics of the group are presented in Table [1](#T1){ref-type="table"}. Two clinical pathologists conducted the pathological evaluations independently. All patients had histologically confirmed LUAD. The classification of LUAD subtypes was conducted following the 2011 International Association for the Study of Lung Cancer (IASLC)/the American Thoracic Society (ATS)/the European Respiratory Society (ERS) guidelines [@B15]. The pathological staging was reassessed with the new international tumor-node-metastasis (TNM) staging system for lung cancer approved by the American Joint Committee on Cancer (AJCC, 7th edition)[@B16]. Primary LUADs and tumor-distant normal lung tissue specimens were obtained from surgically resected lung tissues, which were preserved as formalin-fixed, paraffin-embedded sections, for biomarker and pathologic analyses.

Lung cancer specimens obtained from a clinical molecular diagnostic laboratory were tested for *EGFR* mutations and *ALK* fusion. Genomic DNA and total RNA were extracted from formalin-fixed and paraffin-embedded tissue sections. Mutations in *EGFR* were assessed on genomic DNA, whereas *ALK* fusions were determined with total RNA. The *EGFR* mutations were analyzed by fluorescent real-time PCR using Human EGFR Mutation Detection Kits (AmoyDx, Xiamen, China). ALK fusion variants were detected by multiplex One-step RT-PCR using Human ALK Gene Fusions Detection Kits (AmoyDx). RT-PCR was performed on a 7500 Real Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA), and the absence of *EGFR* mutations and *ALK* fusion was verified by direct sequencing of PCR and RT-PCR products as previously reported [@B17].

Microdissection of lung tissues
-------------------------------

Sections (8-μm) of human lung specimens were cut and transferred to glass slides not coated with polylysine. The slides were stained with Harris hematoxylin for 50 seconds and eosin for 30 seconds and then dried in a laminar flow hood for 5 to 10 min prior to microdissection. For analysis of gene copy number and gene expression, cells (5 × 10^3^) were laser-capture micro-dissected from target tissue sections using the Arcturus PixCell II system (Thermo Fisher Scientific) with an Olympus IX-50 microscope as described previously [@B18]. The time for procurement of micro-dissected tissue for RNA was less than 15 minutes. RNA was extracted with PicoPure RNA extraction kits (Thermo Fisher Scientific) and amplified by RT-PCR. Genomic DNA was extracted from micro-dissected tissue using PicoPure DNA Isolation kits (Thermo Fisher Scientific). The concentrations were measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific).

Quantification of gene copy numbers and mRNA levels
---------------------------------------------------

Quantitative analysis of copy numbers was conducted by QIAGEN qBiomarker Copy Number PCR assays based on a 7500 Real Time PCR System (Thermo Fisher Scientific) as previously described [@B19]. All qBiomarker Copy Number PCR Assays were designed for unique regions of the genome. A qBiomarker Multicopy Reference Copy Number PCR Assay (MRef) was included on each assay. The reference assay recognizes a stable sequence that appears in the human genome more than 40 times and whose copy number is not affected or minimally affected by local genomic changes. Relative gene copy numbers for each specimen were calculated as 2 × T~copy\ number~ (tumor copy number/MRef copy number)/N~copy\ number~ (tumor-distant normal tissue copy number/MRef copy number) from the same patient.

Quantitative RT-PCR (RT-qPCR) of gene expression was performed with a 7500 Real Time PCR System using Power SYBR Green Master Mixture (Thermo Fisher Scientific). Reverse transcription was accomplished with random hemaxmer primers and SuperScript II Reverse Transcriptase kits (Thermo Fisher Scientific). Fold changes were calculated according to the *ΔΔ*CT method [@B20]. For relative gene expression assays, the endogenous control gene was *GAPDH*. The primers used for RT-qPCR are listed in S1 Table.

Retrieval of public genomic datasets
------------------------------------

All datasets used were from publically available sources, including Broad [@B21] (Broad Institute of MIT and Harvard) and MSKCC [@B22] (Memorial Sloan Kettering Cancer Center) or from various projects, including TCGA [@B23], [@B24] (the Cancer Genome Atlas - Cancer Genome) and TSP [@B6] (the Tumor Sequencing Project). The whole-genome/exome or targeted sequencing data for tumors from LUAD and LUSC patients and the clinical and demographic information were extracted from these previous studies (all the sequencing data have been deposited online). For example, DNA sequencing data for the tumors and normal controls and the corresponding clinical information from LUAD patients with spirometry data available in the TCGA cohort were downloaded from gdac.broadinstitute.org.

Analysis of oncogenomic alterations
-----------------------------------

A cross-cancer alteration summary for 23 highly lung cancer-associated genes (selected by QIAGEN within Human Lung Cancer Copy Number PCR Array) was accomplished using c-Bioportal. Data mining was accomplished using cBioPortal [@B25], [@B26] for Cancer Genomics (cBioPortal for Cancer Genomics), available at <http://www.cbioportal.org>, to measure the incidence of conditions that are associated with alterations in these genes. The database query was based on deregulation (amplification, deletion, and mutants) of these genes. Tumor datasets were chosen in accordance with the publication guidelines (last updated on January 17, 2014) of TCGA (tcga\@mail.nih.gov). Generally, sequence variations were mapped to the corresponding genomic coordinates and inspected using the genome browsers of Ensembl ([www.ensembl.org](http://www.ensembl.org)) and NCBI ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). Mutational signature analyses were performed as described previously [@B27]. In brief, mutational catalogues from the genomic sequencing data of primary tumors derived from cohorts of various origins were used to decipher the mutational signatures. The affected mutational process was determined by comparing the extracted signatures with signature sets identified previously (<http://cancer.sanger.ac.uk/cosmic/signatures>) [@B27], [@B28]. Boundaries for deletion, amplification, and complex rearrangements were annotated as previously described [@B6].

Statistical methods
-------------------

Differences of gene copy numbers between paired tumor tissue and tumor-distant normal tissue were tested using the nonparametric Mann-Whitney *U* test. Differences of gene expression between paired tumor tissue and tumor-distant normal tissue were tested by use of the paired two-sample *t* test. The associations between DNA copy numbers and gene expression levels were evaluated by Pearson\'s correlation test. Standard false discovery rate (FDR) and Bonferroni corrections were applied for the analysis of oncogenomic alterations. A *P* value \< 0.05 was considered as statistically significant, and all statistical tests were two-sided. The analyses were performed using SPSS 24, R package, and GraphPad Prism 6.0.

Results
=======

Analysis of somatic alterations for cancer-associated genes in lung cancers
---------------------------------------------------------------------------

Most of the cancer-associated genes affected by copy number alterations (CNAs) are genes in cancer-signaling pathways involved in carcinogenesis and tumor progression [@B29], [@B30]. Thus, we investigated the somatic genomic alterations of 23 lung-cancer related genes in publically available datasets derived from large cohorts of patients with LUAD or LUSC (Fig [1](#F1){ref-type="fig"}). Data mining was accomplished with cBioPortal for Cancer Genomics (available at <http://www.cbioportal.org>) to measure the incidence of conditions that are associated with alterations in these genes. Since the portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression events [@B25], a graph representing a cross-cancer alteration (amplification, deletion, mutation and multiple alterations) for each gene was generated (Fig [1](#F1){ref-type="fig"}).

The focus was on genes whose alterations predispose to susceptibility for lung cancers. The results demonstrated that the oncogenetic profile of lung cancer varies among the histological subtypes, with differences between LUAD and LUSC. Almost half of the checked genes, including *CCND1*, *CSMD1*, *EGFR*, *EMSY*, *MYC*, *PDGFRA*, *PIK3CA*, *PTPRD*, *RB1*, *REL,* and *ZNF217*, displayed multiple alterations (amplification, deletion, and mutation occurring simultaneously). Although there were multiple alterations in the *MYC* gene only in LUSC, various alterations for genes *CCND1*, *EMSY*, *PIK3CA*, and *ZNF217* were present in LUAD. LUAD harbored higher frequencies of amplification of *CCND1*, *PIK3CA*, *FGFR1*, *REL*, and *ZNF217* than LUSC, whereas LUSC harbored higher frequencies of mutations of *EMSY*, *PDGFRA*, and *REL*. In LUAD, the *PTEN* gene, which has rare gene amplification as a tumor suppressor, exhibited higher incidences of mutation and deletion [@B5], [@B6], [@B23], [@B29]. The *VEGFA* gene, whose up-regulation is associated with tumor progression and angiogenesis [@B31], had mutations only in LUSC [@B24]. The genomic alteration patterns varied among the genes. *BCL2L1*, *CCND1*, *CCNE1*, *CDK4*, *ERBB2*, *FGFR1*, *MYC*, *PIK3CA*, *REL*, *VEGFA*, and *ZNF217* predominated in gene amplifications; *CSMD1*, *EGFR*, *MET*, *PDGFRA*, *PRDM1*, *PTPRD*, and *RB1* largely exhibited gene mutations; other genes (*CDKN2A*, *FHIT*, and *PTEN*) had more deletions. These results suggested that LUAD patients harbor distinct somatic alterations in a few genes, which can be exploited for personalized medical care of those patients.

Clinicopathological characteristics of the patients with LUAD without EGFR mutations or ALK fusion
--------------------------------------------------------------------------------------------------

Samples from ten Chinese LUAD patients were used assess the CNAs of the 23 genes. Their clinicopathological characteristics are listed in Table [1](#T1){ref-type="table"}. These patients included five men and five women who had a median age of 55 years (range: 46-72 years). Six patients were never smokers and four were smokers. All tumors from these patients were negative for *EGFR* mutations and *ALK* fusion. The pathological stages were \"Tumor Stage II\" (n=7) and \"Tumor Stage III\" (n=3), with "Moderate\" tumor grade predominating (n=5). Six patients had tumor invasion of local lymph nodes (Table [1](#T1){ref-type="table"}).

Comparative quantification of gene copy numbers in LUAD tumors and corresponding normal lung tissues
----------------------------------------------------------------------------------------------------

To understand the association between the gene copy numbers and lung cancer risk, their association with gene expression levels in normal lung cells were investigated. For LUAD tumor tissues and paired tumor-distant normal lung epithelial tissues from ten LUAD patients, the copy numbers of these genes were quantified by real-time PCR (Table [2](#T2){ref-type="table"} and Fig [2](#F2){ref-type="fig"}). Most of the 23 genes did not show significant changes in CNAs, compared with those for normal lung tissues. *VEGFA*, which is up-regulated in many tumors and correlates with tumor stage and progression [@B31], showed higher copy numbers in LUAD, although without statistical significance (T/N=2.65±0.92, *P*=0.0844). *CDKN2A*, a stabilizer of the tumor suppressor protein p53 [@B32], had a lower abundance in LUAD (T/N=1.66±0.43, *P*=0.0906). In LUAD, the proto-oncogene *MET*, whose amplification and over-expression are associated with various human cancers, including NSCLC [@B33], had lower copy numbers (T/N=1.83±0.26, *P*=0.0603). Three tumor suppressor genes (*PTEN*, *RB1*, and *PTPRD*) and one oncogene (*HMGA2*) had lower copy numbers (all *P*\<0.05) in LUAD tissues (Fig [2](#F2){ref-type="fig"}).

Correlations of copy numbers and mRNA levels for genes with lower copy numbers in LUAD tumors
---------------------------------------------------------------------------------------------

Next, we focused on the lung cancer-associated genes with lower copy numbers in LUAD tissues and measured their expression in LUAD tumor tissues and in paired normal lung epithelial tissues from ten patients with LUAD. Consistent with previous studies [@B6], expressions of the tumor suppressor genes *PTEN* and *RB1* were significantly lower (both *P* \< 0.05) based on comparisons of mRNA levels in tumor and normal tissues (Figs [3](#F3){ref-type="fig"}A and [3](#F3){ref-type="fig"}B). However, for the tumor suppressor gene *PTPRD* and the oncogene *HMGA2* (Figs [3](#F3){ref-type="fig"}C and [3](#F3){ref-type="fig"}D), there were no significant changes in gene expression in LUAD tumors relative to normal tissues (n=6, *P*=0.506 for *PTPRD* and n=8, *P*=0.462 for *HMGA2*). We determined if, in LUAD tumors, the expression of these four genes correlated with their copy numbers. For *PTEN*, there was a significant correlation between these two parameters (R^2^=0.827, *P*=0.003) (Fig [4](#F4){ref-type="fig"}A). The relative expression of *RB1* showed only a marginal association (R^2^=0.2798, *P*=0.1159) with its relative copy numbers (Fig [4](#F4){ref-type="fig"}B), and the copy numbers of *HMGA2* and *PTPRD* showed poor correlations with their expressions (R^2^=0.0514, *P*=0.5286 for *HMGA2*; R^2^=0.0713, *P*=0.4557 for *PTPRD*) (Figs [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D).

Interactions among lung cancer-associated genes based on copy numbers in LUAD without EGFR mutations or ALK fusion
------------------------------------------------------------------------------------------------------------------

Although various genes are associated with LUAD progression, little is known about the underlying regulatory mechanisms [@B12], [@B14]. Thus, Pearson correlation tests were performed to determine the relationship of the 23 lung cancer-associated genes based on their copy numbers in ten LUAD tumors without *EGFR* mutations or*ALK* fusion. The correlation matrix data, presented in S2 Table, contain the results of pairwise comparisons for all 23 genes. Table [3](#T3){ref-type="table"} displays correlations among seven genes that are most likely to interact with each other since they are implicated in tumorigenesis by their effects on cell cycle control and regulation of cellular growth. Most of the pairwise comparisons displayed significant correlations (*P*\<0.05). The correlations of *EMSY*/*CCND1*, *EMSY*/*PIK3CA*, *CCND1*/ *CDKN2A*, and *CCND1*/*PIK3CA* were strong (all *P*\< 0.001). The correlations of *EMSY*/*CCND1*, *EMSY*/ *PIK3CA*, and *CCND1*/*PIK3CA* were all positive (all matrix values \>0.9), as these genes alter cell cycle progression, promote cellular growth, and contribute to tumorigenesis [@B34]-[@B38]. *CDKN2A*, which functions as a tumor suppressor gene, correlated negatively with *CCND1* (matrix value= -0.927, *P*\<0.001).

Discussion
==========

The discovery of driver oncogenes (e.g., *EGFR*, *KRAS*, and *ALK*) has changed the understanding of and the approach to treating lung cancer and has highlighted the importance of the genotype in therapy of lung cancer [@B7], [@B9], [@B10]. However, for LUAD patients without known genomic alterations, it is necessary to identify new therapeutic targets and provide more selective drugs for personal and precise medical care. In this context, the present study presented feasible approaches and introduced a reasonable framework for searching candidate genes and for validating them in a cohort of LUAD patients.

To gain insight into the genomic alterations of the lung cancer-associated genes in normal and malignant tissues without *EGFR* mutation or *ALK* fusion, we evaluated the copy numbers of 23 lung cancer-associated genes in micro-dissected LUAD tumor cells and in tumor-distant normal lung epithelial cells. There were lower copy numbers for four genes: *PTEN*, *RB1*, *PTPRD*, and *HMGA2*. In LUAD tumors, the lower copy numbers of tumor suppressor genes *PTEN*, *RB1*, and *PTPRD* (Fig [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}) are consistent with their oncogenomic profiling results summarized for large cohorts of patients (Fig [1](#F1){ref-type="fig"}). Gene deletions and mutations (indicated by blue bars and green bars, respectively, in Fig [1](#F1){ref-type="fig"},) but not gene amplification (indicated by red bars) predominated in the patterns of alterations for all three genes. Furthermore, the analysis suggested correlations between copy number and expression levels of *PTEN* and *RB1* (Figs [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B), similar to results of previous studies that investigated LUAD tumors regardless of *EGFR*/*ALK* alteration [@B6]. This could be partially or fully attributed to no (for *PTEN*) or rare (for *RB1*) gene amplification found in the genomics of LUAD tumors (Fig [1](#F1){ref-type="fig"}). Our results strengthen the rationale for and importance of developing approaches targeting *PTEN* and*RB1* for treating LUAD without genomic alterations such as *EGFR* mutations and *ALK* fusion. In addition, we also analyzed the copy number of *PTEN*, *RB1*, *HMGA2*, and *PTPRD* using c-Bioportal. Data mining in other categories of lung cancer. Of note, the copy numbers of these genes were also lower in LUSC (Fig. [1](#F1){ref-type="fig"}) but not in large cell carcinoma and small cell carcinoma of the lung.

In view of the lower *PTPRD* expression in LUAD tumors of a few patients (30%, Fig [3](#F3){ref-type="fig"}D) and no correlation between the copy numbers and gene expression levels of *PTPRD* (Fig [4](#F4){ref-type="fig"}D), gene deletion of *PTPRD* (Figs [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) is unlikely to contribute to its expression. Likewise, *HMGA2* displayed reduced copy numbers in LUAD tumors (Table [2](#T2){ref-type="table"} and Fig [2](#F2){ref-type="fig"}), whereas *HMGA2* had a high frequency of gene amplification in lung cancers from large cohorts of patients (Fig [1](#F1){ref-type="fig"}). For a variety of human cancers, *HMGA2*, a transcriptional factor, is positively associated with tumor progression [@B39]-[@B42]. Most LUAD tumors (80%) had higher levels of *HMGA2* mRNA than normal lung tissues (Fig [3](#F3){ref-type="fig"}C), which is consistent with previous reports regarding the role of high *HMGA2* expression in tumorigenicity and onco-transformation [@B43], [@B44]. It raises the question of whether *HMGA2* is a contributor to LUAD tumors without *EGFR*/*ALK* alterations.

LUAD is a complex and heterogeneous disease involving various signaling pathways. Our correlation tests identified a relationship among four genes (*EMSY*, *CCND1*, *PIK3CA*, and *CDKN2A*) based on their copy numbers in ten LUAD tumors without *EGFR* mutations or *ALK* fusion (Table [3](#T3){ref-type="table"}). *EMSY*, a BRCA2-interacting transcriptional repressor, is associated with tumor growth and metastasis [@B34], [@B35]. *CCND1* interacts with its regulator *RB1* to alter cell cycle progression and contributes to tumorigenesis in a variety of tumors [@B36], [@B37]. *CDKN2A* is a tumor suppressor gene involved in regulation of the G1/S phase transition of the cell cycle in human LUAD [@B23], [@B45]. In human cancers,*PIK3CA* and *PTEN*, signaling components of the PI3-kinase pathway, are frequently mutated [@B38]. The present studies confirmed previous findings on the roles of these genes in lung carcinogenesis, which is irrelevant to *EGFR* mutations and *ALK* rearrangements. Since the four strongest correlations (*EMSY*/*CCND1*, *EMSY*/*PIK3CA*, *CCND1*/*CDKN2A*, and *CCND1*/*PIK3CA*) cover either *PIK3CA* or *CCND1*, the results prioritize pathways related to *PTEN*-*PIK3CA* and *RB1*-*CCND1* in developing therapeutic strategies for LUAD patients without *EGFR* mutation or*ALK* fusion.

The current investigation has strengths and limitations. Strengths are that it is the first to report on the oncogenomic aberrations in LUAD patients without *EGFR* mutations or*ALK* fusion and that it provides a framework for searching for and validating lung cancer-associated genes to facilitate implementation of personalized therapy. A limitation is its small sample size of 10 patients. Also, the patients were drawn from a single institution and thus were subject to referral bias. Furthermore, the methodology for quantitation of DNA copy numbers and mRNA levels cannot distinguish gene mutations, since the mutants, rather than deletions of some genes, such as *RB1* (Fig [1](#F1){ref-type="fig"}), act in a dominant-negative manner and are involved in carcinogenesis. Given the inherent bias of intratumor heterogeneity and the presence of variables that we cannot account for, the smaller sample size may lead to missed associations among genomic features of the 23 genes. Nevertheless, although there was a lack of clinical information such as tumor size and tumor location, the current work is the first to quantify genetic aberrations of LUAD tumors that are negative for both *EGFR* mutation and *ALK* fusion. In addition, cigarette smoke and gender are risk factors for lung cancer and cigarette-smoking increases copy number alterations in NSCLC [@B46], [@B47], indicating that these factors may also affect copy numbers of these selected genes.

In conclusions, we conducted an analysis of public datasets to assess the genomic alterations of 23 lung cancer-associated genes and found clues to the etiology and pathogenesis of LUAD and LUSC. We also assessed the oncogenomic profiles of surgically resected tumors without *EGFR* mutations or *ALK* fusion and tumor-distant normal lung tissues from LUAD patients and evaluated possible associations between these candidate genes. Our findings have implications for the molecular stratification and therapeutic targeting of LUAD without *EGFR* mutations or*ALK* fusion. This information also advances understanding of lung carcinogenesis as it relates to oncogenomic CNAs and gene expression and facilitates the identification of personal therapeutic strategies for patients with LUAD.
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![**Public dataset-based analysis of somatic alterations for 23 lung cancer-associate genes associated with lung cancers.** A cross-cancer alteration summary for 23 lung cancer-associated genes was prepared using c-Bioportal. Data mining was accomplished with cBioPortal [@B25], [@B26] for Cancer Genomics, a data portal (cBioPortal for Cancer Genomics) available at <http://www.cbioportal.org>, to measure the incidence of conditions that are associated with the alterations in these genes. The database query was based on deregulation (amplification, deletion, and mutation) of these genes. All datasets used were from publically available sources, including Broad [@B21] (Broad Institute of MIT and Harvard, 183 LUAD samples), MSKCC [@B22] (Memorial Sloan Kettering Cancer Center, 35 LUAD samples) or various projects, including TCGA [@B23], [@B24] (the Cancer Genome Atlas - Cancer Genome, 230 LUAD samples and 178 LUSC samples), TSP [@B6] (the Tumor Sequencing Project, 163 LUAD samples). \"TCGA\" means provisional TCGA datasets; \"TCGA pub\" means TCGA datasets used in the corresponding publications. False discovery rate (FDR) and Bonferroni corrections were applied.](jcav09p1096g001){#F1}

![**Comparative analysis of gene copy numbers in LUADs without *EGFR* mutations or *ALK* fusion.** The copy numbers of 23 lung cancer-associate candidate genes were quantified in micro-dissected tumor cells and paired tumor-distant normal lung epithelial cells from ten LUAD patients without *EGFR* mutation or*ALK* fusion. The y-axis indicates the copy number index calculated by 2 × T~copy\ number~ / N~copy\ number~, where T represents tumor cells and N is the tumor-distant normal lung epithelial cells. Each circle denotes one copy number index of the specified gene from one patient. \* *P* \< 0.05, tumor cells vs. paired tumor-distant normal epithelial cells, tested with the Mann-Whitney *U* test.](jcav09p1096g002){#F2}

![**Comparative analysis of expression for genes with lower copy numbers in LUAD.** Gene expressions were measured in tumor cells and paired tumor-distant normal lung epithelial cells from ten LUAD patients without *EGFR* mutation or*ALK* fusion. A paired *t* test was used to evaluate the correlations of genes expression for *PTEN* (A), *RB1* (B), *HMGA2* (C) and *PTPRD* (D) between tumor tissues (T) and normal lung tissues (N). Each line with paired dot ends indicates the mRNA level change of one patient for the specified gene. *P* values, tumor cells vs. paired tumor-distant normal epithelial cells, were tested using the paired two-sample *t* test.](jcav09p1096g003){#F3}

![**Associations between copy numbers and mRNA levels for *PTEN*, *RB1*, *HMGA2*, and *PTPRD* genes in LUAD without *EGFR* mutation or *ALK* fusion.** The Pearson correlation test was employed to evaluate the association between copy number and gene expression for *PTEN* (A), *RB1* (B), *HMGA2*(C) and *PTPRD* (D) in tumor tissues from ten LUAD patients without *EGFR* mutations or *ALK* fusion. Each dot represents one patient. *P* values for the association between DNA copy numbers and the gene expression levels were evaluated using the Pearson\'s correlation test.](jcav09p1096g004){#F4}

###### 

The clinicopathological characteristics of the LUAD patients.

  Categories                     Case 1     Case 2    Case 3     Case 4    Case 5     Case 6    Case 7    Case 8    Case 9     Case 10
  ------------------------------ ---------- --------- ---------- --------- ---------- --------- --------- --------- ---------- ----------
  Age at the time of diagnosis   50         55        62         46        59         61        72        57        55         52
  Gender                         Female     Male      Male       Female    Male       female    Male      Female    Male       Male
  Race                           Chinese    Chinese   Chinese    Chinese   Chinese    Chinese   Chinese   Chinese   Chinese    Chinese
  Year of diagnosis              2009       2010      2010       2010      2010       2011      2011      2011      2012       2012
  Pathologic type                AD         AD        AD         AD        AD         AD        AD        AD        AD         AD
  EGFR mutation                  No         No        No         No        No         No        No        No        No         No
  ALK rearrangement              No         No        No         No        No         No        No        No        No         No
  Tumor grade                    Moderate   Well      Moderate   Poor      Moderate   Well      Poor      Poor      Moderate   Moderate
  Tumor stage (TNM)              T2N2M0     T2N0M0    T2N0M0     T3N3M0    T2N1M0     T3N1M0    T3N0M0    T2N2M0    T2N0M0     T2N1M0

###### 

Relative gene copy numbers in LUAD cells compared with normal lung epithelial cells from the same patient.

  Gene     T1/N1   T2/N2   T3/N3   T4/N4   T5/N5   T6/N6   T7/N7   T8/N8   T9/N9   T10/N10   Mean   SD     *p*-Value
  -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------- ------ ------ -----------
  BCL2L1   2.60    2.59    1.84    2.07    2.13    2.02    2.62    1.94    1.82    2.20      2.18   0.31   0.1096
  CCND1    1.95    2.14    1.34    1.45    1.68    1.78    26.95   1.66    1.66    1.67      4.23   7.99   0.7085
  CCNE1    2.35    2.31    2.63    2.25    1.41    2.03    3.11    1.98    1.22    2.49      2.18   0.56   0.5746
  CDK4     3.38    2.26    1.99    1.99    1.97    2.10    3.01    1.86    1.52    1.73      2.18   0.58   0.4604
  CDKN2A   2.08    1.88    1.73    1.62    1.76    1.69    0.51    1.79    1.56    1.96      1.66   0.43   0.0906
  CSMD1    2.03    2.30    2.19    3.02    1.67    1.76    2.34    1.90    1.97    1.99      2.12   0.38   0.4288
  EGFR     1.33    1.71    2.10    2.38    1.31    2.09    22.27   1.69    1.56    1.74      3.82   6.49   0.6744
  EMSY     2.27    2.10    1.62    1.76    1.84    1.75    6.47    1.94    1.75    1.92      2.34   1.46   0.6535
  ERBB2    1.54    2.26    1.24    1.64    1.42    2.42    2.85    1.55    1.65    1.86      1.84   0.51   0.2004
  FGFR1    1.79    2.07    1.61    1.79    1.77    1.60    2.79    1.85    1.79    2.46      1.95   0.38   0.5061
  FHIT     2.01    1.91    1.98    2.64    1.85    1.60    1.39    1.92    2.23    1.81      1.93   0.34   0.4057
  HMGA2    1.67    1.80    1.71    1.79    1.29    1.67    1.89    1.67    1.55    1.68      1.67   0.16   0.0004
  MET      2.02    2.06    1.67    1.75    1.42    1.66    2.27    1.92    1.97    1.55      1.83   0.26   0.0603
  MYC      2.44    2.18    1.78    1.66    1.50    2.13    2.63    1.90    2.21    2.10      2.05   0.35   0.8151
  PDGFRA   1.61    3.22    1.83    2.03    1.69    1.60    2.52    2.09    1.69    12.05     3.03   3.21   0.4031
  PIK3CA   1.83    1.82    1.82    1.83    1.61    1.76    3.28    2.29    1.47    1.83      1.95   0.51   0.5144
  PRDM1    2.19    1.54    2.07    2.48    1.41    1.56    2.14    2.02    1.59    2.61      1.96   0.42   0.5693
  PTEN     2.62    1.73    1.88    1.58    1.63    2.12    1.52    1.63    1.32    1.27      1.73   0.40   0.0371
  PTPRD    1.88    1.93    1.89    1.76    1.58    1.83    1.45    1.75    1.62    2.00      1.77   0.17   0.0030
  RB1      2.16    1.56    1.65    1.81    1.78    1.49    1.45    1.78    1.46    1.51      1.67   0.22   0.0010
  REL      2.33    2.00    2.13    2.10    1.96    1.91    2.36    2.16    1.53    1.93      2.04   0.24   0.7388
  VEGFA    1.84    3.96    3.53    3.94    1.36    1.71    2.75    2.07    2.65    2.69      2.65   0.92   0.0844
  ZNF217   2.64    2.55    1.88    1.77    1.48    2.38    2.33    1.91    1.51    2.69      2.11   0.46   0.6502

###### 

Correlation analysis of seven candidate genes based on their copy numbers in tumor tissues of LUAD patients without *EGFR* mutation or *ALK* fusion.

  Interacted Genes   Correlation   P-Value    95% Lower   95% Upper
  ------------------ ------------- ---------- ----------- -----------
  EMSY, CCND1        0.994         \<0.0001   0.974       0.999
  EMSY, CCNE1        0.603         0.0647     -0.043      0.894
  EMSY, CDKN2A       -0.887        0.0002     -0.973      -0.582
  EMSY, FGFR1        0.789         0.0047     0.318       0.948
  EMSY, HMGA2        0.482         0.1648     -0.213      0.853
  EMSY, PIK3CA       0.919         \<0.0001   0.688       0.981
  CCND1, CCNE1       0.587         0.0750     -0.068      0.888
  CCND1, CDKN2A      -0.927        \<0.0001   -0.983      -0.715
  CCND1, FGFR1       0.769         0.0071     0.270       0.942
  CCND1, HMGA2       0.471         0.1762     -0.226      0.849
  CCND1, PIK3CA      0.913         \<0.0001   0.665       0.979
  CCNE1, CDKN2A      -0.397        0.2668     -0.821      0.311
  CCNE1, FGFR1       0.584         0.0770     -0.027      0.887
  CCNE1, HMGA2       0.805         0.0033     0.355       0.952
  CCNE1, PIK3CA      0.695         0.0231     0.117       0.922
  CDKN2A, FGFR1      -0.598        0.0680     -0.892      0.051
  CDKN2A, HMGA2      -0.392        0.2726     -0.820      0.315
  CDKN2A, PIK3CA     -0.804        0.0033     -0.952      -0.353
  CDKN2A, PIK3CA     0.459         0.1891     -0.240      0.845
  FGFR1, PIK3CA      0.731         0.0139     0.187       0.932
  HMGA2, PIK3CA      0.589         0.0738     -0.065      0.889
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